STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novo Nordisk presented a long-term growth strategy at its capital markets day in London, aiming to launch at least five multi-blockbuster drugs by 2030 and match peer-level revenue growth
- Mike Doustdar, Novo Nordisk's CEO, stated the company will increase investments in disease areas beyond diabetes and obesity and become more active in business development to reduce reliance on GLP-1 therapies
- Novo Nordisk plans to market some future products more like consumer goods than traditional pharmaceuticals, leveraging the commercial model emerging around its obesity treatments
- Novo Nordisk's shares dropped 5% during Doustdar’s opening remarks at the investor event, signaling that markets wanted more concrete details despite the strategic announcements
Why it matters: Investors reacted negatively to high-level promises without granular backing—Novo’s 5% share drop during the presentation reveals skepticism about execution. The company must now deliver tangible pipeline progress to justify its ambition of matching big pharma growth rates, especially as it bets on a consumer-driven model beyond prescription dependence.
Ask SkimNews
